LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

Kodu・Aktsiate loetelu・AbbVie Inc

AbbVie Inc

Avatud

SektorTervishoid

216.12 0.45

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

216.04

Max

217.6

Põhinäitajad
By Trading Economics
Sissetulek	-1.1B 697M
Müük	-1.6B 15B
P/E Sektori keskmine	103.158 49.701
Aktsiakasum	2.65
Dividenditootlus	3.2
Kasumimarginaal	4.646
Töötajad	57,000
EBITDA	-635M 4.7B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+18.32% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	3.20% 2.39%
Järgmine tulemuste avaldamine	30. juuli 2026
Järgmine dividendimakse kuupäev	14. aug 2026
Järgmine aktsia dividendi kuupäev (ex-date)	14. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	21B 370B
Eelmine avamishind	215.67
Eelmine sulgemishind	216.12

Uudiste sentiment

By Acuity

23%

77%

39 / 345 Pingereas Healthcare

AbbVie Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2026, 12:38 UTC

Tulu

AbbVie Raises Fiscal Year Guidance on Immunology, Neuroscience Growth

4. veebr 2026, 13:20 UTC

Tulu

AbbVie 4Q Revenue Rises on Immunology Growth

29. apr 2026, 12:41 UTC

Tulu

AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock. -- Barrons.com

29. apr 2026, 12:23 UTC

Tulu

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

29. apr 2026, 11:50 UTC

Tulu

AbbVie Raising Adjusted EPS Guidance for FY26 >ABBV

29. apr 2026, 11:49 UTC

Tulu

AbbVie 1Q Global Humira Rev $688 M >ABBV

29. apr 2026, 11:48 UTC

Tulu

AbbVie 1Q Global Rinvoq Rev $2.119 B >ABBV

29. apr 2026, 11:47 UTC

Tulu

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

29. apr 2026, 11:47 UTC

Tulu

AbbVie 1Q Global Skyrizi Rev $4.48B >ABBV

29. apr 2026, 11:47 UTC

Tulu

AbbVie 1Q Global IMBRUVICA Rev $556M >ABBV

29. apr 2026, 11:47 UTC

Tulu

AbbVie 1Q EPS 39c >ABBV

29. apr 2026, 11:47 UTC

Tulu

AbbVie 1Q Net $695M >ABBV

29. apr 2026, 11:47 UTC

Tulu

AbbVie 1Q International HUMIRA Rev $331M >ABBV

29. apr 2026, 11:47 UTC

Tulu

AbbVie 1Q Rev $15B >ABBV

29. apr 2026, 11:47 UTC

Tulu

AbbVie 1Q Adj EPS $2.65 >ABBV

29. apr 2026, 11:47 UTC

Tulu

AbbVie 1Q U.S. HUMIRA Rev $357M >ABBV

29. apr 2026, 11:47 UTC

Tulu

AbbVie Sees FY Adj EPS $14.08-Adj EPS $14.28 >ABBV

4. veebr 2026, 19:38 UTC

Tulu

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4. veebr 2026, 16:19 UTC

Tulu

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4. veebr 2026, 15:18 UTC

Tulu

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4. veebr 2026, 13:18 UTC

Tulu

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4. veebr 2026, 12:48 UTC

Tulu

AbbVie 4Q U.S. HUMIRA Rev $897M >ABBV

4. veebr 2026, 12:48 UTC

Tulu

AbbVie 4Q Rev $16.62B >ABBV

4. veebr 2026, 12:48 UTC

Tulu

AbbVie 4Q Global IMBRUVICA Rev $671M >ABBV

4. veebr 2026, 12:48 UTC

Tulu

AbbVie 4Q Global Skyrizi Rev $5.01B >ABBV

4. veebr 2026, 12:48 UTC

Tulu

AbbVie 4Q Net $1.82B >ABBV

4. veebr 2026, 12:48 UTC

Tulu

AbbVie 4Q Adj EPS $2.71 >ABBV

4. veebr 2026, 12:48 UTC

Tulu

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.66B >ABBV

4. veebr 2026, 12:48 UTC

Tulu

AbbVie 4Q International HUMIRA Rev $349M >ABBV

4. veebr 2026, 12:48 UTC

Tulu

AbbVie Sees FY Adj EPS $14.37-Adj EPS $14.57 >ABBV

Võrdlus sarnastega

Hinnamuutus

AbbVie Inc Prognoos

Hinnasiht

By TipRanks

18.32% tõus

12 kuu keskmine prognoos

Keskmine 255.22 USD 18.32%

Kõrge 298 USD

Madal 203 USD

Põhineb 20 Wall Streeti analüütiku instrumendi AbbVie Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

Osta

Hoia

Müü

Põhineb 20 analüütiku instrumendi AbbVie Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

39 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.